Data Catalog

B-cells play a pivotal role in several autoimmune diseases, including patients with immune-mediated neurological disorders (PIMND), such as neuromyelitis optica (NMO), multiple sclerosis (MS), and myasthenia gravis (MG). Targeting B-cells has been an effective approach in ameliorating both central and peripheral autoimmune diseases. However, there is a paucity of literature on the safety of continuous B-cell depletion over a long period of time. The aim of this study was to examine the long-term safety, incidence of infections, and malignancies in subjects receiving continuous therapy with a B-cell depleting agent rituximab over at least 3 years or longer. This was a retrospective study involving PIMND who received continuous cycles of rituximab infusions every 6 to 9 months for up to 7 years. The incidence of infection related adverse events (AE), serious adverse events (SAE), and malignancies were observed.

Researchers, students, and others in the Models of Infectious Disease Agent Study (MIDAS) create and use computational models to study transmission dynamics of a broad range of infectious diseases. Many MIDAS members are conducting research on COVID-19 and are contributing to an extraordinary international collection of data and information regarding the outbreak. Through its Online Portal for COVID-19 Modeling Research, MIDAS provides access to COVID-19-related data and parameter estimates as well as a software catalog with a list of dashboards and visualizations for following the COVID-19 pandemic.

Discoidin domain receptor 1 (DDR1) is a collagen-activated receptor tyrosine kinase extensively implicated in diseases such as cancer, atherosclerosis and fibrosis. Multiple preclinical studies, performed using either a gene deletion or a gene silencing approaches, have shown this receptor being a major driver target of fibrosis and glomerulosclerosis. The present study investigated the role and relevance of DDR1 in human crescentic glomerulonephritis (GN). Detailed DDR1 expression was first characterized in detail in human GN biopsies using a novel selective anti-DDR1 antibody using immunohistochemistry. Subsequently the protective role of DDR1 was investigated using a highly selective, novel, small molecule inhibitor in a nephrotoxic serum (NTS) GN model in a prophylactic regime and in the NEP25 GN mouse model using a therapeutic intervention regime.

The Maternal Lifestyle Study (MLS) was the largest of the NIH longitudinal studies of children with prenatal cocaine exposure (PCE). MLS was a longitudinal multi-site observational study of the long-term effects of in-utero exposure to cocaine on child development. MLS was conducted at four geographically diverse, collaborating university centers (Wayne State University, University of Tennessee at Memphis, University of Miami, and Brown University). Participants were identified during the newborn period while in the hospital. The MLS began enrollment of a longitudinal birth cohort of 1,388 infant/mother dyads in 1993. Subjects in the follow-up were seen from 1 month of age through 16 years of age. The overall purpose of the study was to investigate the effects of drug use during pregnancy on acute neonatal events and long-term physical health, social, behavioral and neurodevelopmental outcomes.

The Kids' Inpatient Database (KID) is the largest publicly-available all-payer pediatric inpatient care database in the United States, containing data from two to three million hospital stays. Its large sample size is ideal for developing national and regional estimates and enables analyses of rare conditions, such as congenital anomalies, as well as uncommon treatments, such as organ transplantation.

The Youth Risk Behavior Surveillance System (YRBSS) monitors six categories of health-related behaviors that contribute to the leading causes of death and disability among youth and adults, including behaviors that contribute to unintentional injuries and violence; sexual behaviors related to unintended pregnancy and sexually transmitted diseases, including HIV infection; alcohol and other drug use; tobacco use; unhealthy dietary behaviors; and inadequate physical activity. YRBSS also measures the prevalence of obesity and asthma and other health-related behaviors plus sexual identity and sex of sexual contacts. YRBSS includes a national school-based survey conducted by CDC and state, territorial, tribal, and local surveys conducted by state, territorial, and local education and health agencies and tribal governments.